Aardvark Therapeutics (AARD) Q2 2026 earnings summary

Executive summary

• Clinical-stage biopharma focused on small-molecule therapeutics for metabolic diseases, with lead candidate ARD-101 targeting hunger pathways via TAS2Rs.

• Phase 3 HERO and OLE trials for ARD-101 in Prader-Willi Syndrome were paused and terminated in June 2026 after FDA clinical hold due to reversible cardiac observations; company is assessing unblinded data and remains in active FDA discussions to determine next steps.

• No products approved or revenue generated to date; company expects continued net losses as it pursues regulatory strategy and potential new trials.

Financial highlights

• Net loss for Q2 2026 was $14.4 million, flat compared to Q2 2025; net loss for the six months ended June 30, 2026 was $36.0 million, up from $23.7 million in the prior year period.

• R&D expenses decreased to $10.5 million in Q2 2026 from $13.1 million in Q2 2025 due to paused clinical trials; G&A expenses increased to $4.6 million from $2.7 million year-over-year, driven by personnel costs and severance.

• Cash, cash equivalents, and short-term investments totaled $73.9 million as of June 30, 2026, down from $91.2 million as of March 31, 2026.

• Accumulated deficit reached $151.9 million as of June 30, 2026.

Outlook and guidance

• Existing cash and investments expected to fund operations into late 2027, but additional capital will be needed for future development and commercialization.

• Future expenditures and capital needs depend on regulatory outcomes, assessment of unblinded ARD-101 trial data, and ongoing FDA discussions.